Clinical Trial Update: A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cannabidiol for acutely ill schizophrenia patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Central Institute of Mental Health, Mannheim | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED